Immune checkpoint inhibitors (ICIs), which interact with the anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis to reactivate the immune response, have emerged as a novel therapeutic option in patients with non-small cell lung cancer (NSCLC) (1). This evidence concerns the gene CD274 and non-small cell lung carcinoma.